苯达莫司汀在慢性淋巴细胞白血病和非霍奇金淋巴瘤中的应用。

Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphoma.

机构信息

Georgetown University Hospital, Lombardi Comprehensive Cancer Center, 3800 Reservoir RD, NW, Washington, DC 20007, USA.

出版信息

Expert Rev Anticancer Ther. 2010 Sep;10(9):1353-65. doi: 10.1586/era.10.116.

DOI:10.1586/era.10.116

PMID:20836669

Abstract

Bendamustine (Treanda(®); Pharmachemie BV, The Netherlands for Cephalon, Inc., PA, USA) is a unique cytotoxic agent with both alkylating and antimetabolite properties. A growing body of evidence demonstrates its efficacy in a number of hematologic malignancies, and as such, it has been US FDA approved for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma that has not responded to, or progressed within 6 months of, a rituximab-based regimen. Bendamustine has efficacy both as a single agent as well as in combination with other chemotherapeutics and immunotherapeutics. Here, we will discuss in the detail the molecular properties, clinical efficacy and safety profile of bendamustine.

摘要

苯达莫司汀（Treanda ® ；荷兰 Pharmachemie BV 公司为美国宾夕法尼亚州 Cephalon 公司生产）是一种具有烷化剂和抗代谢物特性的独特细胞毒性药物。越来越多的证据表明其在多种血液系统恶性肿瘤中的疗效，因此，它已获得美国食品药品监督管理局批准，用于治疗对利妥昔单抗为基础的方案无反应或在 6 个月内进展的慢性淋巴细胞白血病和非霍奇金淋巴瘤。苯达莫司汀作为单一药物以及与其他化疗药物和免疫治疗药物联合使用均具有疗效。在这里，我们将详细讨论苯达莫司汀的分子特性、临床疗效和安全性概况。